Home » Stocks » SUPN

Supernus Pharmaceuticals, Inc. (SUPN)

Stock Price: $21.76 USD 0.09 (0.42%)
Updated December 3, 4:00 PM EST - Market closed

SUPN Stock Price Chart

Key Info

Market Cap 1.15B
Revenue (ttm) 477.29M
Net Income (ttm) 129.31M
Shares Out 52.66M
EPS (ttm) 2.41
PE Ratio 9.03
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $21.76
Previous Close $21.67
Change ($) 0.09
Change (%) 0.42%
Day's Open 21.77
Day's Range 21.58 - 22.28
Day's Volume 365,095
52-Week Range 14.45 - 25.05

SUPN Stock News

Business Wire - 2 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $SUPN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) ...

Business Wire - 2 weeks ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $SUPN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

GlobeNewsWire - 2 weeks ago

ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

Business Wire - 2 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $SUPN #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc (SUPN) on Behalf o...

GlobeNewsWire - 3 weeks ago

ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

PRNewsWire - 3 weeks ago

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investo...

GlobeNewsWire - 3 weeks ago

ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

Seeking Alpha - 4 weeks ago

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 month ago

Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 month ago

ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

GlobeNewsWire - 1 month ago

ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

GuruFocus - 1 month ago

Investors who are looking for high return investments might be interested in the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt's method) a...

Other stocks mentioned: ENIA, TKC
GlobeNewsWire - 1 month ago

Greg Patrick to Retire as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer

Seeking Alpha - 2 months ago

Supernus is solidly on track for a new record of net sales this year and is still generating huge amounts of free cash flow.

The Motley Fool - 2 months ago

These stocks are just temporarily inconvenienced large caps in the making.

Other stocks mentioned: ADUS, INVA
Investopedia - 2 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, MNTA, NLTX, PRGO, RLMD, SNY, TAK
GlobeNewsWire - 2 months ago

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

GlobeNewsWire - 2 months ago

ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

Seeking Alpha - 3 months ago

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Supernus (SUPN) delivered earnings and revenue surprises of 85.71% and 0.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...

Zacks Investment Research - 3 months ago

Supernus (SUPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 4 months ago

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 4 months ago

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 4 months ago

Gold, silver, miners/GSMs outperformed nicely in Q2, and should continue to do extremely well going forward.

Other stocks mentioned: AGI, BIDU, FSM, GDXJ, NOV, PAAS, SLB, TSLA
GlobeNewsWire - 5 months ago

ROCKVILLE, Md., June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...

InvestorPlace - 5 months ago

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

Other stocks mentioned: CORT, DVAX, GTHX, IMGN, KDMN, VRTX
GlobeNewsWire - 5 months ago

Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline Creates leading CNS portfolio with five marketed products, two ...

Seeking Alpha - 6 months ago

Supernus Offers Strong Value In The CNS Space

GlobeNewsWire - 6 months ago

ROCKVILLE, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment ...

Seeking Alpha - 6 months ago

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Supernus (SUPN) delivered earnings and revenue surprises of 33.33% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 7 months ago

A Super 'Pick-Up' By Supernus

GlobeNewsWire - 7 months ago

ROCKVILLE, Md., April 28, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

Zacks Investment Research - 7 months ago

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 7 months ago

These two underrated biotech stocks have the potential to soar.

Other stocks mentioned: KPTI
GlobeNewsWire - 7 months ago

ROCKVILLE, Md. and CAMBRIDGE, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing prod...

GlobeNewsWire - 8 months ago

ROCKVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

Seeking Alpha - 9 months ago

Jazz Pharma's Mixed Earnings, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: JAZZ, SEEL
The Motley Fool - 9 months ago

Shares slumped after the commercial-stage biopharma reported mixed results.

Seeking Alpha - 9 months ago

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Supernus (SUPN) delivered earnings and revenue surprises of 8.77% and -6.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 10 months ago

SPN-812 (viloxazine hydrochloride), a once-daily novel serotonin norepinephrine modulating agent (SNMA), demonstrates a reduction in ADHD-RS-5 total score as early as Week 1 and continuing unt...

Zacks Investment Research - 10 months ago

Is Supernus Pharmaceuticals (SUPN) a great pick from the value investor's perspective right now? Read on to know more.

GlobeNewsWire - 11 months ago

ROCKVILLE, Md., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...

GlobeNewsWire - 1 year ago

SPN-812 (viloxazine hydrochloride), a novel serotonin norepinephrine modulating agent (SNMA) SPN-812 (viloxazine hydrochloride), a novel serotonin norepinephrine modulating agent (SNMA)

Seeking Alpha - 1 year ago

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

About SUPN

Supernus Pharmaceuticals, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its prod... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 1, 2012
CEO
Jack Khattar
Employees
464
Stock Exchange
NASDAQ
Ticker Symbol
SUPN
Full Company Profile

Financial Performance

In 2019, SUPN's revenue was $392.76 million, a decrease of -3.95% compared to the previous year's $408.90 million. Earnings were $113.06 million, an increase of 1.86%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is 27.75, which is an increase of 27.53% from the latest price.

Price Target
$27.75
(27.53% upside)
Analyst Consensus: Buy